Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Ketamine for OCD
NCT02234011Phase 2
Key facts
- Status
- Terminated
- Start
- Sep 2014
- Primary completion
- Jan 2016
- Countries
- 1
- Sponsor
- McLean Hospital
- Modality
- Small Molecules
- Drugs
- ketamine
- Conditions
- obsessive compulsive disorder (OCD)
01
Overview
Phase 2, randomised, double-blind trial of ketamine in obsessive compulsive disorder (OCD) (2 arms), sponsored by McLean Hospital. Primary endpoint: Decrease in OCD Symptoms at 5 weeks. Started Sep 2014; status: terminated.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Ketamine/Placebo
Ketamine at Visit 1, Placebo at Visit 2
Placebo/Ketamine
Placebo at Visit 1, Ketamine at Visit 2
03
Who it enrols
Adults aged 18-55 with a primary diagnosis of OCD and a Y-BOCS score >= 18. Excludes patients with active suicidal ideation, history of psychotic or autism spectrum disorders, substance dependence, or significant medical/neurologic disease.
04
Endpoints
Primary
Decrease in OCD Symptoms
Beyond the preview
Go deeper on NCT02234011.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02234011.